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With permission: G Jagschies et al., “Biopharmaceutical Processing: 




>65 population by 
2.3 bn (until 2100) 
in Asia and Africa
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#4 - Beyond antibodies









HTPD*, QbD*, PAT* Integration SUT* standards
E&L* service standards





equipment, no bespoke 
solutions
Minimal piping
smaller & less tanks
Matching demand increase or new market entry
In- and at-line analytics

















#5 - Upstream process
Cell line development (CLD) Cell culture, batch
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• Reduction of CLD time from 40 
weeks (traditional) to 10 weeks
• Less screening: more projects, 
more time for difficult to express 
proteins
• Product quality, not just titer !!!
• Titers reach or exceed 10 g/L
• Advanced approaches to boost 
viable cell density
• Fine tuning ”nutrition”
• Time compression for 
inoculation train and production 
reactor
Cell culture, perfusion
• Foot print reduction ~50% (5-10 
fold vol reduction)
• Elevated volumetric productivity
(3-5 g/L/day) and reduced 
perfusion rate (0.2-0.5 RV/day)
• Mitigate perceived or real 
business risks via simplification 
(e.g., iSKID)
API
Capture Viral  
inactivation






Each step in the 
process







#10 - Disease challenges far from solved
Unlikely for any company to address these challenges alone!
Lose against antimicrobial resistance? Win over cancer?






Biotherapeutics for the most complex diseases we know, such as cancer or diseases of the nervous system, are still in the earlier phases of their 
efficacy and potency related “learning curves.” Consequently, additional generations of biotherapeutics will have to be developed before one may 
hope for victory over those diseases or even for regularly bringing patients back to a status where life with the disease is long-term manageable.
Biopharmaceutical Processing (just 
published)
Günter Jagschies, Eva Lindskog, Parrish Galliher and Karol Łącki










100 authors, 1.200 pages
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